Sean Maduck serves as the President of Corcept Endocrinology at CORCEPT THERAPEUTICS INC, a pioneering company focused on the development and commercialization of treatments for severe metabolic, oncologic, and psychiatric disorders. With a robust background in pharmaceuticals and biotechnology, Maduck has been instrumental in steering Corcept's efforts in endocrinology. Prior to joining Corcept, he held significant leadership roles at various renowned pharmaceutical companies, where he honed his skills in strategic planning, product development, and market expansion. In his current role at Corcept, Maduck oversees the company's initiatives aimed at advancing treatments for endocrine disorders. His leadership has been pivotal in the development and launch of innovative therapies that address unmet medical needs, particularly in the field of Cushing's syndrome. Under his guidance, Corcept has successfully expanded its portfolio and strengthened its position as a leader in endocrinology. Maduck's strategic vision and dedication to improving patient outcomes have earned him recognition within the industry and contributed significantly to the company's growth and success. Maduck's achievements extend beyond his corporate responsibilities. He is actively involved in various professional organizations and frequently participates in industry conferences, where he shares insights on the latest advancements in endocrinology and pharmaceuticals. His commitment to advancing medical science and his ability to lead cross-functional teams have made him a respected figure in the field. Through his work at Corcept, Maduck continues to drive innovation and improve the lives of patients suffering from severe endocrine disorders.